Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Arthritis & Rheumatology(2025)10.1002/art.43219Source: DataRank Database

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus is a research paper published in Arthritis & Rheumatology (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

omim

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.64)OA: hybridTopics (41)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Mieke van Schaik ORCID,Annemarie L Dorjée,Eline J. Arends ORCID,Meggan Mackay ORCID,Laura Cooney

Live enrichment

PubMed:40356198 PMC:PMC12353765 OpenAlex:https://openalex.org/W4410332081

National Institutes of Health

Grant: UM1‐AI‐109565

NIAID NIH HHS

Grant: UM1 AI109565

NIH HHS

Grant: UM1-AI-109565

National Institutes of Health

Grant: 3UM1AI109565-09S1

Immune Tolerance Network

Leiden University Medical Center

FWCI

2.64

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.43219

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.43219

publisherhttps://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.43219

journalhttps://doi.org/10.1002/art.43219

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40356198

Fields of Study

Systemic Lupus Erythematosus ResearchCytomegalovirus and herpesvirus researchMultiple Sclerosis Research Studies03 medical and health sciences0302 clinical medicine

MeSH Terms

RituximabAdultAntibodies, AntinuclearB-LymphocytesFemaleHumansImmunosuppressive AgentsLongitudinal StudiesLupus Erythematosus, SystemicMaleMiddle AgedAntibodies, Monoclonal, Humanized

Keywords

AntibodyTiterBelimumabImmunologyMedicineRituximabSeroconversionB cellVirologySystemic lupus erythematosusInternal medicineDiseaseB-cell activating factorMaleAdultB-LymphocytesMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, AntinuclearHumansLupus Erythematosus, SystemicFemaleLongitudinal StudiesImmunosuppressive Agents

Sustainable Development Goals

SDG 0: Good health and well-being

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

FAIR Checklist

Authors (17)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)